96 related articles for article (PubMed ID: 8549611)
1. Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats.
Majima M; Ikeda Y; Kuribayashi Y; Mizogami S; Katori M; Aoyagi T
Eur J Pharmacol; 1995 Sep; 284(1-2):1-11. PubMed ID: 8549611
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of kinin degradation on the luminal side of renal tubules reduces high blood pressure in deoxycorticosterone acetate salt-treated rats.
Nakajima S; Ito H; Hayashi I; Kuribayashi Y; Okumura T; Yajima Y; Katori M; Majima M
Clin Exp Pharmacol Physiol; 2000; 27(1-2):80-7. PubMed ID: 10696533
[TBL] [Abstract][Full Text] [Related]
3. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.
Ito H; Majima M; Nakajima S; Hayashi I; Katori M; Izumi T
Br J Pharmacol; 1999 Feb; 126(3):613-20. PubMed ID: 10188971
[TBL] [Abstract][Full Text] [Related]
4. Role of the renal kallikrein-kinin system in the development of hypertension.
Katori M; Majima M
Immunopharmacology; 1997 Jun; 36(2-3):237-42. PubMed ID: 9228552
[TBL] [Abstract][Full Text] [Related]
5. Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension.
Katori M; Majima M; Hayashi I
Biol Res; 1998; 31(3):143-9. PubMed ID: 9830501
[TBL] [Abstract][Full Text] [Related]
6. Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Nakajima S; Majima M; Ito H; Hayashi I; Yajima Y; Katori M
Int J Tissue React; 1998; 20(2):45-56. PubMed ID: 9638501
[TBL] [Abstract][Full Text] [Related]
7. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats.
Majima M; Yoshida O; Mihara H; Muto T; Mizogami S; Kuribayashi Y; Katori M; Oh-ishi S
Hypertension; 1993 Nov; 22(5):705-14. PubMed ID: 7693588
[TBL] [Abstract][Full Text] [Related]
8. In vivo transfer of antisense oligonucleotide against urinary kininase blunts deoxycorticosterone acetate-salt hypertension in rats.
Hayashi I; Majima M; Fujita T; Okumura T; Kumagai Y; Tomita N; Morishita R; Higaki J; Ogiwara T
Br J Pharmacol; 2000 Oct; 131(4):820-6. PubMed ID: 11030733
[TBL] [Abstract][Full Text] [Related]
9. Role of the renal kallikrein-kinin system in the development of salt-sensitive hypertension.
Katori M; Majima M; Hayashi I; Fujita T; Yamanaka M
Biol Chem; 2001 Jan; 382(1):61-4. PubMed ID: 11258674
[TBL] [Abstract][Full Text] [Related]
10. Essential role of kallikrein-kinin system in suppression of blood pressure rise during the developmental stage of hypertension induced by deoxycorticosterone acetate-salt in rats.
Katori M; Majima M; Mohsin SS; Hanazuka M; Mizogami S; Oh-ishi S
Agents Actions Suppl; 1992; 38 ( Pt 3)():235-42. PubMed ID: 1281379
[TBL] [Abstract][Full Text] [Related]
11. Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention.
Majima M; Hayashi I; Fujita T; Ito H; Nakajima S; Katori M
Immunopharmacology; 1999 Oct; 44(1-2):145-52. PubMed ID: 10604538
[TBL] [Abstract][Full Text] [Related]
12. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system.
Majima M; Katori M; Hanazuka M; Mizogami S; Nakano T; Nakao Y; Mikami R; Uryu H; Okamura R; Mohsin SS
Hypertension; 1991 Jun; 17(6 Pt 1):806-13. PubMed ID: 1710605
[TBL] [Abstract][Full Text] [Related]
13. An ATP-sensitive potassium channel blocker suppresses sodium-induced hypertension through increased secretion of urinary kallikrein.
Kamata Y; Fujita T; Kato T; Hayashi I; Kurosaka M; Katori M; Fujita Y; Majima M
Hypertens Res; 2009 Mar; 32(3):220-6. PubMed ID: 19262486
[TBL] [Abstract][Full Text] [Related]
14. Increase in vascular sensitivity to angiotensin II and norepinephrine after four-day infusion of 0.3 M sodium chloride in conscious kininogen-deficient brown Norway Katholiek rats.
Majima M; Adachi K; Kuribayashi Y; Mizogami S; Katori M
Jpn J Pharmacol; 1995 Oct; 69(2):149-58. PubMed ID: 8569052
[TBL] [Abstract][Full Text] [Related]
15. Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats.
Majima M; Mizogami S; Kuribayashi Y; Katori M; Oh-ishi S
Hypertension; 1994 Jul; 24(1):111-9. PubMed ID: 8020999
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of the third kininogen in high and low molecular weight kininogens-deficient Brown Norway Katholiek rat.
Hayashi I; Ino T; Kato H; Iwanaga S; Nakano T; Oh-ishi S
Thromb Res; 1984 Dec; 36(6):509-16. PubMed ID: 6570369
[TBL] [Abstract][Full Text] [Related]
17. Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats.
Rhaleb NE; Yang XP; Nanba M; Shesely EG; Carretero OA
Hypertension; 2001 Jan; 37(1):121-128. PubMed ID: 11208766
[TBL] [Abstract][Full Text] [Related]
18. Suppression of dextran sulfate sodium-induced colitis in kininogen-deficient rats and non-peptide B2 receptor antagonist-treated rats.
Kamat K; Hayashi I; Mizuguchi Y; Arai K; Saeki T; Ohno T; Saigenji K; Majima M
Jpn J Pharmacol; 2002 Sep; 90(1):59-66. PubMed ID: 12396028
[TBL] [Abstract][Full Text] [Related]
19. Kininogen deficiency in the rat.
Oh-ishi S; Hayashi I; Yamaki K; Utsunomiya I
Agents Actions Suppl; 1992; 38 ( Pt 1)():277-91. PubMed ID: 1281609
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats.
Ito H; Hayashi I; Izumi T; Majima M
Br J Pharmacol; 2003 Jan; 138(1):225-33. PubMed ID: 12522094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
